Zepbound Reviews: What Patients, Doctors and the Trials Each Say

Most pages ranking for this query show you one pool of reviews: their own. A patient review site shows patient stars, a physician network shows physician stars, and the manufacturer shows testimonials. None of them puts the three next to each other, which is a shame, because the comparison is where the signal is. Below is that table, with every figure taken from the source page on the date given.

Zepbound ratings across three independent sources

The two rating sources were collected from completely different populations by completely different methods, and they produce the same shape. Whatever measures does it work comes out near the top. Whatever measures can you tolerate it and can you get it comes out near the bottom. That is the finding, and it is more useful than any single star average.

The satisfaction gap, in the patient numbers

WebMD splits its stars into three questions, and the split is the most informative thing on the page. For effectiveness, 71% of reviewers gave 5 stars and 10% gave 1 star. For satisfaction, 52% gave 5 stars and 15% gave 1 star. The same people, asked two questions about the same medicine, answered nineteen points apart at the top and five points apart at the bottom.

Effectiveness asks whether the weight came off. Satisfaction asks whether the whole thing was worth it, and that folds in nausea, refill hassle, price and coverage. A star average of 4.2 hides both numbers.

The same gap, in the physician numbers

Sermo scores five dimensions separately: efficacy 4.3, safety 4.0, adherence 4.0, tolerability 3.7 and accessibility 2.8. Accessibility is the lowest score by a full point, from 407 doctors who are not paying for the drug themselves and have no reason to complain about price on their own behalf. When the prescriber and the patient independently rank access as the weakest part of a treatment, that is not a grumble, it is a property of the treatment.

What the trials measured, since reviews cannot

Reviews tell you what a self-selected group felt. Trials tell you what happened to everyone enrolled, including the people who quit. Both matter, and the trial numbers are the anchor you should read the stars against.

In SURMOUNT-1, 2,539 adults with obesity, or with overweight plus a weight-related complication, and without diabetes, were randomised to weekly tirzepatide or placebo for 72 weeks. Mean weight change at week 72 was -15.0% on the 5 mg group, -19.5% on 10 mg and -20.9% on 15 mg, against -3.1% on placebo. A reduction of 5% or more occurred in 85% to 91% of the tirzepatide groups and 35% on placebo. A reduction of 20% or more occurred in 50% of the 10 mg group and 57% of the 15 mg group, against 3% on placebo.

The discontinuation figure is the one reviews structurally cannot give you. Adverse events ended treatment for 4.3%, 7.1% and 6.2% of the three tirzepatide groups, against 2.6% on placebo. Those people mostly do not write reviews, which is exactly why a review pool reads more positive than a trial population.

The four things no Zepbound review can tell you

This is the part the ranking pages skip, and it is the reason a 9 out of 10 average is less reassuring than it sounds.

1. There is no denominator. A rating page shows you the people who chose to post. It cannot show you the people who stopped in week six and never came back to the site. The trial discontinuation rates above are your best estimate of the size of that missing group.
2. Most reviews do not state a dose or a duration. Someone three weeks into a starting dose and someone fourteen months into a maintenance dose are describing different experiences under the same star rating.
3. A review is a snapshot, not a trajectory. The most common complaints, gastrointestinal effects, were reported in the trial as mostly mild to moderate and concentrated during the dose-escalation period. A review written during escalation and one written after it will disagree without either being wrong.
4. Nobody reviews the part that happens later. In SURMOUNT-4, 670 participants lost a mean 20.9% during a 36-week lead-in, then either continued tirzepatide or moved to placebo. Between week 36 and week 88, the continued group changed a further -5.5% while the placebo group regained 14.0%. A reviewer at month three has not lived that yet and cannot tell you about it.

How to read a Zepbound review in four questions

If you are going to read reviews anyway, and you should, these four questions separate the ones worth weighting from the ones worth skipping.

• How long have they been on it? Under twelve weeks, you are probably reading about dose escalation rather than about the medicine at a steady dose.
• Do they name the problem or the feeling? "Nausea on day two, gone by day four" is data. "Didn't agree with me" is not.
• Is the complaint about the drug or about the system? Prior authorisation, pharmacy supply and price are real problems and they are the ones both patients and physicians rate worst, but they say nothing about whether the medicine works.
• Would this person's starting point resemble yours? The trial excluded people with diabetes, and tirzepatide is also sold as Mounjaro for type 2 diabetes. Reviews from the two populations often sit in the same pile and are not interchangeable.

Reddit reviews specifically

Reddit threads are the one place people post the week-by-week detail the star sites strip out, which makes them genuinely better than a rating page for the question "what does week three feel like". They are worse for everything else. There is no verification, heavy selection toward people having a notable experience in either direction, and no way to know how many quiet users never posted. Treat a thread as a list of things that can happen, not as a frequency estimate.

Before-and-after reviews specifically

Photographs carry no timeline, no starting weight, no dose and no information about what else changed. The SURMOUNT-1 range above is the honest version of the same question, with a denominator attached. If a before-and-after post does not state how many weeks passed, it is not telling you anything you can compare yourself to.

The only review that describes you is the one you write

Every limitation above comes from the same root: a review is someone else's data, collected without a protocol, about a body that is not yours. The fix is unglamorous. Keep your own record from the first dose, so that at week twelve you are reading your own trajectory instead of a stranger's snapshot.

Three fields are enough to make that record useful: the date and dose of each injection, where you injected it, and any symptom with the day it appeared. Logged together, they answer the questions reviews cannot. Did the nausea track dose changes or was it random. Is the weekly rate of change still moving. Did that sore spot follow a particular site.

This is what Jabby is built to do. It logs the dose and the date, maps which injection site you used so rotation is a record rather than a memory, and attaches side effects to the dose they followed, which is the pairing that turns a diary into an answer. At the next appointment it exports as a history your prescriber can read in a minute.

Frequently asked questions

What is the average Zepbound rating?

It depends entirely on who is being asked. On WebMD, 48 patient reviews average 4.2 out of 5, with about 83% reporting a positive effect. On Sermo, 407 physicians average 3.8 out of 5. Both were read on 29 September 2026. A single average across sites does not exist and would not mean much if it did, because the populations and the questions differ.

Are the complaints about Zepbound mostly about side effects?

They split into two groups. Gastrointestinal effects were the most common adverse events in the trial, described as mostly mild to moderate and occurring primarily during dose escalation. The second group is access: cost, insurance and supply. The physician ratings support that second group being substantial, with accessibility at 2.8 out of 5, the lowest score on the board.

Is Zepbound the same as Mounjaro?

Both are tirzepatide from Eli Lilly, approved under different brand names for different conditions. That matters when reading reviews, because reviews written by people treating type 2 diabetes and reviews written by people treating obesity describe different goals and often different starting points.

Do the good reviews keep holding up over time?

The evidence on that specific question comes from SURMOUNT-4 rather than from reviews. Participants who continued tirzepatide after a 36-week lead-in changed a further -5.5% between weeks 36 and 88, while those switched to placebo regained 14.0%. Whether that pattern applies to you is a conversation with your prescriber.

Why are Drugs.com figures not in the table above?

Because we could not load the page to read them. Several pages ranking for this query quote a Drugs.com average, and the figures they quote do not match each other. We only publish numbers we opened ourselves, so that source is left out rather than repeated second hand.

Should reviews decide whether I start?

No. Reviews are useful for learning which problems come up often enough to plan around, and useless as a prediction of your own result. Eligibility, the risks that apply to you and the choice of medicine are decisions for your prescriber, working from the approved labelling.

Related reading

• Tirzepatide guide, the molecule behind both Zepbound and Mounjaro
• Zepbound KwikPen needles, what fits the pen and how many you need
• Zepbound injection site reactions, the rates by dose and how to tell a local reaction from hypersensitivity
• Does Zepbound cause headaches?, the trial figures read against the placebo group
• Mounjaro vs Ozempic vs Wegovy, how the options compare
• Semaglutide side effects, the comparison many readers reach for next
• Best GLP-1 app, for logging dose, weight and symptoms in one place

Sources

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022 Jul 21;387(3):205-216. PMID 35658024. DOI 10.1056/NEJMoa2206038. ClinicalTrials.gov NCT04184622.
• Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48. PMID 38078870. DOI 10.1001/jama.2023.24945. ClinicalTrials.gov NCT04660643.
• WebMD, Zepbound (Tirzepatide) user reviews and ratings page. Read 29 September 2026: 4.2 out of 5 from 48 reviews; effectiveness 5 stars 71%; ease of use 5 stars 77%; satisfaction 5 stars 52%.
• Sermo, Zepbound drug ratings page. Read 29 September 2026: 3.8 out of 5 from 407 physician ratings; efficacy 4.3, safety 4.0, adherence 4.0, tolerability 3.7, accessibility 2.8.